Biocon Limited has announced the allotment of 11,26,64,585 equity shares at a face value of ₹5 each, priced at ₹368.35 per share, raising approximately ₹41,500 million through a Qualified Institutions Placement (QIP). The QIP opened on January 12, 2026, and closed on January 14, 2026. Post-allotment, the equity share capital of the company has increased.
Equity Share Allotment
Biocon Limited has approved the issue and allotment of 11,26,64,585 Equity Shares to eligible qualified institutional buyers. The face value of each share is ₹5, and they were issued at a price of ₹368.35 per Equity Share, including a premium of ₹363.35. The total amount aggregated to ₹41,500 million.
Issue Details and Capital Increase
The issue opened on January 12, 2026, and closed on January 14, 2026. Following the allotment, the company’s paid-up Equity Share capital increased from ₹7,54,12,15,940 (consisting of 1,50,82,43,188 Equity Shares) to ₹8,10,45,38,865 (consisting of 1,62,09,07,773 Equity Shares).
Key Allottees
Several allottees received more than 5% of the equity shares offered in the issue. These include:
- SBI Contra Fund: 11,266,460 shares (10.0000%)
- SBI Multicap Fund: 9,773,314 shares (8.6747%)
- SBI ELSS Tax Saver Fund: 4,072,215 shares (3.6145%)
- ICICI Prudential Value Fund: 13,981,271 shares (12.4096%)
- ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund: 10,587,759 shares (9.3976%)
Note: Percentages might not add up to 100% due to other allottees receiving less than 5%.
Committee Meeting Conclusion
The Committee meeting related to this allotment commenced at 11:40 p.m. and concluded at 11:45 p.m. on January 14, 2026.
Source: BSE
